Controlled ovarian stimulation with r-FSH plus r-LH vs. HMG plus r-FSH in patients candidate for IVF/ICSI cycles: An RCT
- PMID: 29177245
- PMCID: PMC5601935
Controlled ovarian stimulation with r-FSH plus r-LH vs. HMG plus r-FSH in patients candidate for IVF/ICSI cycles: An RCT
Abstract
Background: Different combination of gonadotropin preparation has been introduced with no definite superiority of one over others in in vitro fertilization (IVF), but individualized regimens for each patient are needed.
Objective: The aim of the present study was to investigate the effect of controlled ovarian stimulation with recombinant- follicle stimulating hormone (r-FSH) plus recombinant-luteinizing hormone (rLH) versus human menopausal gonadotropin (HMG) plus r-FSH on fertility outcomes in IVF patients.
Materials and methods: This is a randomized clinical trial study that was performed from October 2014-April 2016 on 140 infertile patients with a set of inclusion criteria that referred to infertility clinics in Vali- asr and Gandhi Hospital in Tehran. The women were randomly divided into two treatment groups. The first group (n=70) received rFSH from the second day of cycle and was added HMG in 6th day and the 2nd group (n=70), received rFSH from the second day of cycle and was added recombinant-LH in 6th day. Then ovum Pick-Up and embryo transfer were performed. In this study, we assessed the outcomes such as; chemical and clinical pregnancy rate, live birth and abortion rate.
Results: Number of follicles in ovaries, total number of oocytes or M2 oocytes and quality of fetuses has no significant differences between two groups (p>0.05). Total number of fetuses were significantly higher in patients who received rFSH + HMG (p=0.02). Fertility outcomes consisted of: live birth rate, chemical pregnancy and clinical pregnancy rate were higher in rFSH + HMG group in comparison to rFSH +r-LH group (p<0.05).
Conclusion: It seems that in IVF patients, HMG + rFSH used for controlled ovarian hyperstimulation have better effects on fertility outcomes, but in order to verify the results, it is recommended to implement studies on more patients.
Keywords: Human menopausal gonadotropin; ICSI; IVF; Ovulation induction; Recombinant-FSH; Recombinant-LH.
Conflict of interest statement
It should be noted that there was no association between the authors and any organization or institution. The Authors report no declarations of interest.
Similar articles
-
[Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].Zhonghua Fu Chan Ke Za Zhi. 2013 Nov;48(11):838-42. Zhonghua Fu Chan Ke Za Zhi. 2013. PMID: 24444561 Chinese.
-
Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.Cochrane Database Syst Rev. 2017 May 24;5(5):CD005070. doi: 10.1002/14651858.CD005070.pub3. Cochrane Database Syst Rev. 2017. PMID: 28537052 Free PMC article. Review.
-
Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women ≥35 years: a RCT.Hum Reprod. 2015 Jan;30(1):179-85. doi: 10.1093/humrep/deu302. Epub 2014 Nov 14. Hum Reprod. 2015. PMID: 25398971 Clinical Trial.
-
Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.Hum Reprod. 2015 May;30(5):1188-95. doi: 10.1093/humrep/dev038. Epub 2015 Mar 3. Hum Reprod. 2015. PMID: 25740882 Clinical Trial.
-
Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles.Cochrane Database Syst Rev. 2003;(1):CD003973. doi: 10.1002/14651858.CD003973. Cochrane Database Syst Rev. 2003. PMID: 12535497 Updated. Review.
Cited by
-
Luteinizing hormone supplementation in women with hypogonadotropic hypogonadism seeking fertility care: Insights from a narrative review.Front Endocrinol (Lausanne). 2022 Aug 1;13:907249. doi: 10.3389/fendo.2022.907249. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35979440 Free PMC article. Review.
-
Randomized controlled trial comparing embryonic quality in rFSH versus hMG in the IVF protocol with GnRH Antagonist.JBRA Assist Reprod. 2021 Feb 2;25(1):131-135. doi: 10.5935/1518-0557.20200064. JBRA Assist Reprod. 2021. PMID: 33118716 Free PMC article. Clinical Trial.
-
Prolonged pituitary down-regulation with full-dose of gonadotropin-releasing hormone agonist in different menstrual cycles: a retrospective cohort study.PeerJ. 2019 Apr 29;7:e6837. doi: 10.7717/peerj.6837. eCollection 2019. PeerJ. 2019. PMID: 31106057 Free PMC article.
References
-
- Revelli A, Pettinau G, Basso G, Carosso A, Ferrero A, Dallan C, et al. Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human MenopausalGonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population. Reprod Biol Endocrinol. 2015;13:77. - PMC - PubMed
-
- Filicori M, Fazleabas AT, Huhtaniemi I, Licht P, Rao ChV, Tesarik J, et al. Novel concepts of human chorionic gonadotropin: reproductive system interactions and potential in the management of infertility. Fertil Steril. 2005;84:275–284. - PubMed
-
- Platteau P, Andersen AN, Balen A, Devroey P, Sørensen P, Helmgaard L, et al. Menopur Ovulation Induction (MOI) Study Group. Similar ovulation rates, butdifferent follicular development with highly purified menotrophin compared withrecombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Hum Reprod. 2006;21:1798–1804. - PubMed
-
- Pacchiarotti A, Sbracia M, Frega A, Selman H, Rinaldi L, Pacchiarotti A. Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH(pergoveris) in IVF: a multicenter, prospective, randomized controlled trial. Fertil Steril. 2010;94:2467–2469. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous